JP2023527741A - アミロイドーシスの治療 - Google Patents

アミロイドーシスの治療 Download PDF

Info

Publication number
JP2023527741A
JP2023527741A JP2022570279A JP2022570279A JP2023527741A JP 2023527741 A JP2023527741 A JP 2023527741A JP 2022570279 A JP2022570279 A JP 2022570279A JP 2022570279 A JP2022570279 A JP 2022570279A JP 2023527741 A JP2023527741 A JP 2023527741A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
compound
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527741A5 (cg-RX-API-DMAC7.html
Inventor
デュアン バンカー，ケビン
アブディ サマター，アフメド
ロバート ピンチマン，ジョセフ
キンファ ファン，ピーター
Original Assignee
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー filed Critical リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Publication of JP2023527741A publication Critical patent/JP2023527741A/ja
Publication of JP2023527741A5 publication Critical patent/JP2023527741A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Steroid Compounds (AREA)
JP2022570279A 2020-05-19 2021-05-17 アミロイドーシスの治療 Pending JP2023527741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027194P 2020-05-19 2020-05-19
US63/027,194 2020-05-19
PCT/US2021/032808 WO2021236543A1 (en) 2020-05-19 2021-05-17 Treatment for amyloidosis

Publications (2)

Publication Number Publication Date
JP2023527741A true JP2023527741A (ja) 2023-06-30
JP2023527741A5 JP2023527741A5 (cg-RX-API-DMAC7.html) 2024-05-23

Family

ID=78708017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570279A Pending JP2023527741A (ja) 2020-05-19 2021-05-17 アミロイドーシスの治療

Country Status (12)

Country Link
US (1) US20230210846A1 (cg-RX-API-DMAC7.html)
EP (1) EP4138837A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023527741A (cg-RX-API-DMAC7.html)
KR (1) KR20230013102A (cg-RX-API-DMAC7.html)
CN (1) CN116133661A (cg-RX-API-DMAC7.html)
AU (1) AU2021273731A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023486A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183746A1 (cg-RX-API-DMAC7.html)
IL (1) IL298297A (cg-RX-API-DMAC7.html)
MX (1) MX2022014468A (cg-RX-API-DMAC7.html)
TW (1) TW202207931A (cg-RX-API-DMAC7.html)
WO (1) WO2021236543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199899A1 (en) * 2018-04-09 2019-10-17 Case Western Reserve University Bioink and crosslinkable support medium for printing
WO2019199907A1 (en) * 2018-04-10 2019-10-17 Dow Global Technologies Llc Dispenser for can with fixed valve stem housing
WO2019199902A1 (en) * 2018-04-10 2019-10-17 Facebook, Inc. Automated decisions based on descriptive models

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316472A (en) * 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199899A1 (en) * 2018-04-09 2019-10-17 Case Western Reserve University Bioink and crosslinkable support medium for printing
WO2019199907A1 (en) * 2018-04-10 2019-10-17 Dow Global Technologies Llc Dispenser for can with fixed valve stem housing
WO2019199902A1 (en) * 2018-04-10 2019-10-17 Facebook, Inc. Automated decisions based on descriptive models

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 132, no. 1, JPN6025019783, 2018, ISSN: 0005597221 *
BR. J. HAEMATOL., vol. 189, JPN6025019785, February 2020 (2020-02-01), pages 1136 - 1140, ISSN: 0005597222 *
INT. J. HEMATOL., vol. 112, JPN6025019784, March 2020 (2020-03-01), pages 234 - 237, ISSN: 0005597223 *

Also Published As

Publication number Publication date
WO2021236543A1 (en) 2021-11-25
MX2022014468A (es) 2023-02-09
IL298297A (en) 2023-01-01
US20230210846A1 (en) 2023-07-06
BR112022023486A2 (pt) 2023-01-10
CN116133661A (zh) 2023-05-16
KR20230013102A (ko) 2023-01-26
AU2021273731A1 (en) 2022-12-15
TW202207931A (zh) 2022-03-01
EP4138837A4 (en) 2024-05-22
EP4138837A1 (en) 2023-03-01
CA3183746A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7750526B2 (ja) 組み合わせ
JP2023508325A (ja) 組み合わせ
JP7631348B2 (ja) 組み合わせ
JP2023526283A (ja) 単独療法及び併用療法
JP2023508327A (ja) 組み合わせ
JP2023507797A (ja) 組み合わせ
US20230210846A1 (en) Treatment for amyloidosis
JP2023507799A (ja) 組み合わせ
JP2023508331A (ja) 組み合わせ
JP2023545498A (ja) Ｂｃｌ－２阻害剤と化学療法剤との組み合わせ
KR20230007360A (ko) 복합제
JP2023508324A (ja) 組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251118